Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line docetaxel + oxaliplatin in advanced non-small cell lung cancer
2007-001123-35Phase 2Terminated
- Sponsor
- Fondazione Luigi Maria Monti IDI-IRCCS
- Start
- Oct 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and oxaliplatin in non-small cell lung cancer (NSCLC), sponsored by Fondazione Luigi Maria Monti IDI-IRCCS. Primary endpoints: response rate and toxicity evaluation. Started Oct 2007; status: terminated.
02
Drugs
docetaxeloxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-001123-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001123-35.